Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues

Cancer

Volumn 77, Issue 6, 1996, Pages 1079-1088

  Costantini, Vincenzo ^a   Sidoni, Angelo ^a   Deveglia, Roberta ^a   Cazzato, Ornella A ^a   Bellezza, Guido ^a   Ferri, Ivana ^a   Bucciarelli, Emilio ^a   Nenci, Giuseppe G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Breast cancer; Neoplasm progression; Urokinase; Urokinase receptor

Indexed keywords

AVIDIN; BIOTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

BREAST; BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; ENZYME PRECURSORS; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029968743     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1079::AID-CNCR12>3.0.CO;2-Z     Document Type: Article

References (41)

1. Dano K, Andreasen PA, Grondhal-Hansen J, Kristensen P, Nielsen LS, Skyiver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
2. Liotta LA, Steeg PS. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
3. Pollanen J, Stephens RW, Vaheri A. Direct plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
4. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Pysiol Rev 1991;73:161-95.
5. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989;49:2533-53.
6. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987;104:801-4.
7. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993;15:105-11.
8. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surface: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1993;103:2411-20.
9. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface bound urokinase. J Cell Biol 1988;107:2437-45.
10. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991;115:1107-12.
11. Quax PHA, Pedersen N, Masucci MT, Weening-Werhoeff EJD, Dano K, Verheijen J, et al. Complementation of urokinase and its receptor in extracellular matrix degradation. Cell Regulation 1991;2:793-803.
12. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U.S.A. 1993;90:5021-5.
13. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54:3066-71.
14. Kariko K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 1993;53:3109-17.
15. Cohen RL, Xi XP, Crowley CW, Lucas BK, Levinson AD, Shuman MA. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991;78:479-87.
16. Costantini V, Zacharski LR, Memoli VA, Kudryk BJ, Rousseau SM, Stump DC. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res 1991;51:354-8.
17. Pyke C, Graem N, Ralfkiaer N, Hoeyer-Hansen G, Brunner N, Dano K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-5.
18. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993;53:3198-206.
19. Bianchi E, Cohen RL, Thor AT, Todd III RF, Mizukami IF, Lawrence DA, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994;54:861-6.
20. Jankun J, Merrick HW, Goldblatt PJ. Expression and localization of elements of the plasminogen activation system in benign breast disease and in breast cancers. J Cell Biochem 1993;53:135-44.
21. Chucholowski N, Schmitt M, Rettenberger P, Schuren E, Moniwa N, Groetzki L, et al. Flow cytofluorometry analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent uPA ligand or monoclonal antibody 3936. Fibrinolysis 1992;6(4 Suppl):95-102.
22. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991;266:5147-52.
23. de Vries TJ, Quax PHA, Denijin M, Verrijp KN, Verheijen JA, Verspaget HW, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81.
24. Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991;51:349-53.
25. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty K. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988;90:233-9.
26. Colton T. Statistics in medicine. Boston: Little, Brown, and Co., 1974.
27. Costantini V, Cazzato AO, Pasqualini ME, DeMonte P, Mariotti M, DeVeglia R, et al. Functional and immunological evaluation of fibrinolysis pathway components in extracts of benign and malignant breast tissues: a comparison between cytosolic and membrane-bound reactants [abstract]. Thromb Haemost 1995;73:1461.
28. Zhang S, Laurent M, Lopez-Alemany R, Mazar A, Henkin J, Ronne E, et al. Comparative localization of receptors for plasmin and for urokinase on MCF7 cells. Exp Cell Res 1993;207:290-9.
29. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1993;265:6453-60.
30. 2-terminal domain of the urokinase receptor. FEBS Lett 1991;288:233-6.
31. Tissot JD, Hauert J, Bachmann F. Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer 1984;34:295-302.
32. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:111-7.
33. Dano K, Behrendt N, Ellis V, Eriksen J, Hoyer-Hansen G, Kristensen P, et al. The role of u-PA and its receptor in tissue remodeling and tumor invasion [abstract]. Fibrinolysis 1992;6(2 Suppl):23.
34. Janicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990;4:69-78.
35. Ossowski L, Biegel D, Reich E. Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979;16:929-40.
36. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-12.
37. Janicke F, Schmitt M, Fache L, Ulm K, Harbeck N, Hofler H, et al. Urokinase CuPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
38. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
39. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
40. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992;50:208-14.
41. Kirchlheimer JC, Wojta Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in human melanoma cell line. Proc Natl Acad Sci U S A 1989;86:5424-8.